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Introduction
RNA  interference  (RNAi)  is  an  evolutionarily  conserved 
mechanism  of  gene  regulation  by  which  small  double-
stranded RNA (dsRNA) molecules—termed small interfering 
RNAs (siRNAs)—degrade complementary messenger RNA 
to silence gene expression.1 By using siRNAs as therapeutic 
compounds, it is possible to block the production of disease-
causing  proteins.  As  such,  RNAi  is  being  implemented  in 
clinical trials for the treatment of a variety of diseases (e.g., 
hypercholesterolemia, cancer, etc.).2
Lipidic-based vectors are the preferred approach for siRNA 
delivery in vitro and in vivo. Precise formulation of siRNAs 
with  lipid,  polyethylene  glycol-lipid,  and  cholesterol  allows 
encapsulation into liposomal nanoparticles for improved bio-
availability.3 Although this method is preferably utilized to tar-
get the liver, lipid formulations have been applied to efficiently 
deliver siRNA to solid tumors in mice.4 Further development 
has also led to an enhanced class of lipid-like molecules—
termed lipidoids—with refined delivery functions.5,6 Currently, 
lipidoid 95N12-5(1) is considered a leading material for effec-
tive in vivo delivery of siRNA.
Safe strategies to selectively enhance gene and/or protein 
production remain a challenge in gene therapy. Viral-based 
systems have inherent drawbacks including adverse effects 
on host genome integrity, immunological consequences, etc. 
Recently, small dsRNAs have also been shown to induce 
gene  expression  in  a  phenomenon  referred  to  as  RNA 
activation (RNAa).7–10 Several models of RNAa have been 
described  including  transcriptional  activation  by  targeting 
promoter  sequences7,8,11,12  and/or  overlapping  noncoding 
transcripts.13–15 This technique offers a similar approach as 
RNAi, while representing a new strategy to stimulate gene 
expression.
Cyclin-dependent kinase (CDK) inhibitor p21WAF1/CIP1 
(p21) is a mediator of several anti-growth pathways including 
cell cycle arrest.16 The effects of p21 are partially mediated 
through the retinoblastoma (Rb) protein, which is inactivated 
in  proliferating  cells  by  phosphorylation.17  By  directly  sup-
pressing CDK activity, p21 promotes Rb hypophosphorylation 
leading to cell cycle arrest. In normal cells, p21 participates in 
several cellular processes including controlled growth, differ-
entiation, and senescence.16,18,19 However, p21 is considered 
a potent tumor suppressor gene in cancer cells.20 Ectopic 
expression of p21 has been shown to inhibit tumor growth 
both in vitro and in vivo, as well as induce apoptosis.21,22
Disruption  of  the  Rb  pathway  is  frequent  in  human 
  cancers23;  however,  loss-of-function  mutations  to  p21  are 
generally a rare occurrence.24–26 In this regard, p21 may be 
an ideal target for RNAa to inhibit tumor cell growth. Although 
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previous studies have implemented this technique in vitro,27,28 
it is unclear if RNAa is applicable in vivo using clinically rel-
evant delivery systems. In the present study, we screen sev-
eral dsRNAs in order to identify a strong activator of p21 
expression for in vivo delivery into human prostate xenograft 
tumors. We provide insight into the stepwise creation of a 
candidate  dsRNA  with  improved  medicinal  properties  and 
potent antiproliferative effects in prostate cancer cells. Addi-
tional molecular experiments assess sequence requirement 
and  validate  the  dependency  of  growth  inhibition  on  p21 
induction. Subsequent delivery assays reveal lipidoid-based 
formulation mediates p21 induction and suppresses xeno-
graft tumor growth. Our results provide proof-of-principle that 
lipidoids have application in delivering RNA duplexes in vivo 
to facilitate RNAa, as well as highlight a candidate RNAa-
based drug with antitumor activity.
Results
Characterization of chemically modified dsRNA designed 
to induce p21 expression
It has been previously reported that p21 is susceptible to 
gene induction by targeting promoter sequence with dsRNA.7 
In order to identify a strong activator of p21, we designed sev-
eral dsRNAs according to published design rules7,11 that tar-
geted sites −208, −254, −280, −322, −365, −402, −422, and 
−466 bp relative to the p21 transcription start site (Figure 1a). 
Each duplex was named according to its target within the p21 
promoter (i.e., dsP21-208, dsP21-254, etc.). A nonspecific 
dsRNA (dsCon) was also synthesized to serve as a control. 
Each duplex was transfected into PC-3 (prostate adenocar-
cinoma) cells and gene expression was evaluated 72 hours 
later. As shown in Figure 1b,c, dsP21-365 and dsP21-422 did 
not significantly augment p21 expression; however, dsP21-
254, dsP21-280, dsP21-322, and dsP21-402 resulted in vari-
able levels of gene induction. Conversely, both dsP21-208 
and dsP21-466 had a reciprocal effect downregulating p21 
expression by ~80%—a feature reminiscent of transcriptional 
gene silencing mediated by small RNA29 (Figure 1b,c). Over-
all, dsP21-322 was the strongest activator of p21 expression 
elevating levels in excess of 14-fold (Figure 1b,c). As such, 
dsP21-322 was selected for further evaluation.
Chemical modification is often required to improve the effi-
cacy and medicinal properties of duplex RNAs. Modification to 
the 2′ position in the ribose backbone (e.g., 2′-fluoro) is utilized 
to improve nuclease resistance and reduce stimulation of the 
innate immune response.30 To improve the medicinal features 
of dsP21-322, we created a fully modified dsP21-322 (dsP21-
322-2′F-S/AS) in which all cytidine and uridine nucleosides 
within the duplex contained a 2′-fluoro-modified ribose sugar 
(Supplementary Figure S1a). However, dsP21-322-2′F-S/
AS suffered from inferior function as it possessed less than 
half the activity of dsP21-322 (Supplementary Figure S1b). 
It has been previously reported that excessive modification to 
the passenger strand in dsRNA molecules can interfere with 
RNAa activity.31 As such, we synthesized another modified 
dsP21-322 (dsP21-322-2′F) in which only the cytidines and 
uridines in the antisense strand—  previously identified as the 
guide strand31—contained 2′-fluoro-modifications (Figure 2a). 
Transfection  of  dsP21-322-2′F  induced  p21  expression  to 
levels similar to unmodified dsP21-322 (Figure 2b,c). Immu-
noblot analysis also confirmed an increase in p21 protein 
levels  (Figure  2d).  Because  PC-3  cells  possess  wild-type 
Rb  protein  that  is  inactivated  by  hyperphosphorylation,32 
we also evaluated Rb phosphorylation status. As shown in 
  Figure 2d, dsP21-322 and dsP21-322-2′F caused a consid-
erable reduction in phosphorylated Rb (P-Rb) levels suggest-
ing p21 activation results in a fully functional protein capable 
of manipulating Rb activity.
To test the medicinal benefits of dsP21-322-2′F, we eval-
uated  its  nuclease  sensitivity  in  active  mouse  serum.  As 
shown  in  Figure  2e,  dsP21-322-2′F  was  stable  for  up  to 
8 hours in serum compared to unmodified dsP21-322. Even 
at 24 hours, low levels of dsP21-322-2′F duplex remained 
detectable (Figure 2e). Quantification of duplex decay esti-
mated the half-life of dsP21-322-2′F to be ~14 hours, while 
dsP21-322 was only ~6 hours (Supplementary Figure S2). 
To evaluate its immune stimulatory effects, human peripheral 
blood mononuclear cells isolated from donor patients were 
transfected  with  dsP21-322-2′F  and  tested  for  IFN-α  and 
100 bp
p21
GAPDH
CpG island
TATA
+1
−
4
6
6
M
o
c
k
d
s
C
o
n
dsP21−208
dsP21−254
dsP21−280
dsP21−322
dsP21−365
dsP21−402
dsP21−422
dsP21−466
M
o
c
k
R
e
l
a
t
i
v
e
 
p
2
1
 
e
x
p
r
e
s
s
i
o
n
d
s
C
o
n
d
s
P
2
1
−
2
0
8
dsP21−254
dsP21−280
dsP21−322
dsP21−365
d
s
P
2
1
−
4
0
2
d
s
P
2
1
−
4
2
2
d
s
P
2
1
−
4
6
6
−
4
2
2
−
4
0
2
−
3
6
5
−
3
2
2
−
2
8
0
−
2
5
4
−
2
0
8
*
*
*
*
*
*
15
12
9
6
3
0
a
b
c
Figure  1  Promoter-targeting  dsRNA  and  p21  expression. 
(a) Schematic representation of the p21 promoter including CpG 
  island and TATA box. Indicated are the locations of each dsRNA 
  target  site  relative  to  the  transcription  start  site  (+1).  (b)  PC-3 
cells were transfected at 50 nmol/l concentrations of the   indicated 
  duplexes  for  72  hours.  Mock  samples  were  transfected  in  the 
  absence of dsRNA. Expression levels of p21 and GAPDH were 
  assessed by semi-quantitative RT-PCR. GAPDH served as a load-
ing  control.  (c)  Relative  expression  of  p21  was  determined  by 
real-time PCR (mean ± SD from three independent experiments). 
Values of p21 were normalized to GAPDH. The dotted line repre-
sents baseline levels. Statistical significance was determined by 
two-tailed t-test against control treatments (*P < 0.01). dsRNA, 
double-stranded  RNA;  GAPDH,  glyceraldehyde  3-phosphate 
  dehydrogenase; RT-PCR, reverse transcription-PCR.www.moleculartherapy.org/mtna
Lipidoid-mediated Delivery of Small Activating RNA
Place et al
3
tumor necrosis factor-α (TNF-α) production by enzyme-linked 
immunosorbent assay. Several duplexes previously identified 
to be strong activators of IFN-α and/or TNF-α were utilized as 
positive controls, while another duplex with no immune stimu-
latory effect was used as a negative control.33,34 As shown in 
Figure 2f, unmodified dsCon and dsP21-322 induced robust 
IFN-α and TNF-α production similar to the positive controls, 
while  cytokine  stimulation  was  tremendously  reduced  in 
dsP21-322-2′F and dsCon-2′F treatments. Taken together, 
these results indicate that dsP21-322-2′F possesses activity 
similar to its unmodified form with enhanced nuclease stabil-
ity and reduced immune stimulatory effects.
To characterize dsP21-322-2′F potency, we calculated its 
EC50 (half maximal effective concentration) value by mea-
suring p21 expression levels following transfection at accu-
mulating  concentrations  in  PC-3  cells.  Percent  response 
was determined by setting the maximum and minimum p21 
expression values to 100 and 0% activity, respectively. As 
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Figure 2  Activity and medicinal properties of dsP21-322-2′F. (a) Sequence composition of dsP21-322-2′F. Indicated are the sense 
(S) and antisense (AS) strands, which possess dual deoxythymidine overhangs at their 3′-termini. Lowercase letters in bold correspond 
to 2′-fluoro-modified nucleotides. (b) PC-3 cells were transfected at 50 nmol/l concentrations of dsCon, dsCon-2′F, dsP21-322, or dsP21-
322-2′F for 72 hours. Mock samples were transfected in the absence of dsRNA. Expression levels of p21 and GAPDH were assessed by 
semi-quantitative RT-PCR. GAPDH served as a loading control. (c) Relative expression of p21 was determined by real-time PCR (mean ± 
SD from three independent experiments). Values of p21 were normalized to GAPDH. (d) Protein levels of p21, phorphorylated Rb (P-Rb), 
total Rb, and GAPDH were evaluated by immunoblot analysis using protein-specific antibodies. (e) Equal quantities of dsP21-322 and 
dsP21-322-2′F were diluted in active mouse serum and incubated at 37 °C for the indicated lengths time. Duplex stability was visualized on 
an agarose gel. (f) Human PBMC cells were transfected with 133 nmol/l concentrations of each indicated dsRNAs for 24 hours. Levels of 
IFN-α and TNF-α were assessed by ELISA. Known strong activators of IFN-α (IFN) and/or TNF-α (TNF) served as positive controls (Pos). 
A duplex with no immune stimulatory effect acted as a negative control (Neg Con). Results from the most responsive donor are shown.   
(g) PC-3 cells were transfected with accumulating concentrations of dsP21-322-2′F for 72 hours. Expression of p21 was quantified by real-
time PCR (mean ± SD from two independent experiments). Maximum and minimum levels of induction correlate to 100 and 0% response, 
respectively. Nonlinear regression analysis was utilized to generate best fit line. Duplex concentration is shown in log scale. Dotted lines 
illustrate approximate EC50. dsRNA, double-stranded RNA; EC50, half maximal effective concentration; ELISA, enzyme-linked immuno-
sorbent assay; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IFN-α, interferon-α; PBMC, peripheral blood mononuclear cell; Rb, 
retinoblastoma; RT-PCR, reverse transcription-PCR; TNF-α, tumor necrosis factor-α.Molecular Therapy–Nucleic Acids
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shown in Figure 2g, the estimated EC50 of dsP21-322-2′F 
was ~1 nmol/l in PC-3 cells at 72 hours.
Inhibition of prostate cancer cell growth by  
dsP21-322-2′F
Overexpression of p21 is known to suppress cell proliferation, 
as well as promote cell death.21,22 Quantitative analysis by 
MTS assay revealed that cell viability steadily decreased fol-
lowing dsP21-322-2′F transfection in PC-3 cells   (Figure 3a). 
Elevated  and  sustained  expression  of  p21  correlated 
with  reduced  viability  by  dsP21-322-2′F    (Supplementary 
  Figure  S3a,b).  Cells  also  appeared  less  dense  and  dis-
played  larger,  flattened  morphologies  that  continued  to 
enlarge  by  day  7;  phenotypes  indicative  of  impeded  cell 
growth   (Supplementary Figure S3c). Clonogenicity assays 
also revealed that dsP21-322-2′F prevented colony formation 
compared to control treatments (Figure 3b).
To evaluate cell cycle distribution, DNA content was ana-
lyzed by flow cytometry in cells stained with propidium iodide 
following dsP21-322-2′F transfection. As shown in Figure 3c,d, 
dsP21-322-2′F caused G0/G1 arrest in PC-3 cells as indicated 
by the increase in G0/G1 cell number and concurrent declines 
in  S  and  G2/M  populations.  Further  analysis  of  the  entire 
gated whole-cell population revealed a significant increase in 
the subdiploid fraction of dsP21-322-2′F-treated cells sugges-
tive of DNA fragmentation and cell death (Figure 3c,d).
Overexpression  of  p21  has  also  been  linked  to  cellular 
senescence.18,19 To evaluate induced senescence, PC-3 cells 
were transfected with dsP21-322-2′F and stained for senes-
cence-associated β-galactosidase (SA-β-gal) activity. As shown 
in Figure 3e, PC-3 cells stained positive for SA-β-gal activity fol-
lowing dsP21-322-2′F treatment. In contrast, SA-β-gal staining 
in mock and dsCon-2′F treatments were nearly undetectable.
Susceptibility to p21 induction and inhibition of cell growth 
by dsP21-322-2′F was also assessed in prostate cancer cell 
lines  with  different  genetic  backgrounds  including  DU-145 
(prostate carcinoma) and LNCaP (prostate adenocarcinoma) 
cells. Analysis of messenger RNA expression revealed that 
p21  levels  increased  by  five  and  fourfold  in  LNCaP  and 
DU-145 cells, respectively (Supplementary Figure S4a,b). 
Figure 3  dsP21-322-2′F reduces prostate cancer cell viability and growth. (a) PC-3 cells were transfected with 50 nmol/l concentra-
tions of dsCon-2′F or dsP21-322-2′F and seeded in 96-well microplates. Mock samples were transfected in the absence of dsRNA. Cell 
viability was quantified at each day utilizing MTS reagent. Data is plotted as the mean ± SE of two independent experiments relative to 
  untreated cells. (b) PC-3 cells were plated at ~2,500 cells in 30 mm tissue culture dishes and transfected the following day. Cells were 
grown for ~11 days and analyzed for colony formation by staining with crystal violet. Shown are representative photographs taken of tissue 
culture plates from each treatment group. (c) PC-3 cells were transfected with mock, dsCon-2′F, or dsP21-322-2′F for 72 hours. Floating 
and   attached cells were collected, stained with PI, and processed for analysis by flow cytometry to measure DNA content. Shown are 
examples of resulting FL2A histograms. (d) Flow cytometry data was analyzed to determine cell cycle distribution (mean ± SD from four 
independent experiments). Percentages of sub-G1 cells were calculated from entire gated whole-cell populations, whereas cell cycle distri-
bution (G0/G1, S, and G2/M) was determined from only surviving cells. Statistical significance was determined by two-tailed t-test against 
control treatments (*P < 0.01; **P < 0.05). (e) PC-3 cells were transfected with dsRNA for 3 days, fixed in formaldehyde, and stained for   
SA-β-gal activity overnight. Images were captured by bright field microscopy at ×200 magnification. Dark perinuclear staining marks senes-
cent cells. dsRNA, double-stranded RNA; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; 
PI, propidium iodide; SA-β-gal, senescence-associated β-galactosidase.
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In addition, dsP21-322-2′F also caused a steady reduction 
in LNCaP and DU-145 cell viability (Supplementary Figure 
S4c). Taken together, these results indicate that dsP21-322-
2′F has putative antitumor activity in several different prostate 
cancer cell lines.
Sequence requirement of dsP21-322-2′F
To test the general sensitivity of p21 to nonspecific sequences, 
we blindly screened 11 additional RNA duplexes (dsRNA-1 
to dsRNA-11) with defined and undefined activities for the 
capability to induce p21 levels. Overall, p21 was not respon-
sive  to  nonspecific  duplex  treatment;  only  dsRNA-4  and 
dsRNA-8 minimally increased p21 levels by approximately 
two  to  threefold  (Supplementary  Figure  S5a). This  data 
suggests that activation of p21 is not a general consequence 
of dsRNA treatment, but rather specific to the sequence of 
dsP21-322-2′F.
To  define  the  sequence  requirement  of  dsP21-322-2′F, 
several mismatched mutants (dsP21-322-MM1 to dsP21-322
-MM9) were synthesized and evaluated for the ability to acti-
vate p21 expression. Each mutant possessed three tandem 
nucleotide mismatches relative to the intended target site in 
the p21 promoter that partially overlapped with the mutation 
site in the preceding mutant duplex (Supplementary Figure 
S5b). As shown in Supplementary Figure S5c, none of the 
mutant  derivatives  possessed  heightened  activity.  Rather, 
mutation within the “seed” sequence (dsP21-322-MM3) and 
3′-flanking  region  (dsP21-322-MM6  and  dsP21-322-MM7) 
completely prevented p21 induction, while mismatches cor-
responding to the center (dsP21-322-MM5) and 3′-terminal 
end (dsP21-322-MM9) of the duplex had no impact on activ-
ity.  In  addition,  the  remaining  duplexes  (dsP21-322-MM1, 
dsP21-322-MM2, dsP21-322-MM4, and dsP21-322-MM8) all 
possessed reduced function (Supplementary Figure S5c). 
Based on this data, two internal sequences roughly corre-
sponding to nucleotides 1–7 and 12–16 relative to the 5′-end 
of the antisense strand are required for optimal induction of 
p21 (Supplementary Figure S5d).
Growth inhibition of dsP21-322-2′F is dependent on p21 
induction
Mutant  derivatives  (Supplementary  Figure  S5b,c)  that 
retained  mid-to-strong  p21  induction  activity  (dsP21-322-
MM1, dsP21-322-MM4, dsP21-322-MM5, dsP21-322-MM8, 
and  dsP21-322-MM9)  acquired  morphological  changes 
similar  to  dsP21-322-2′F  (Supplementary  Figure  S6a). 
Duplexes with low (dsP21-322-MM2) or no capacity to acti-
vate  p21  expression  (dsP21-322-MM3,  dsP21-322-MM6, 
and dsP21-322-MM7) correlated with minimal or no visible 
changes  in  cell  phenotype,  respectively  (Supplementary 
Figure  S6a).  Quantitative  analysis  revealed  that  declines 
in cell viability also correlated to the capacity of dsP21-322-
2′F and its mutant derivatives to activate p21 expression—
dsP21-322-MM3 being the only derivative that had no impact 
on p21 induction, but retained a partial inhibitory function on 
PC-3 cell viability (Supplementary Figure S6b). Collectively, 
these results suggest that the growth inhibitory function of 
dsP21-322-2′F correlates with p21 induction.
Cotreatment  with  siRNA  targeting  p21  messenger  RNA 
may be utilized to counteract p21 induction by dsP21-322-
2′F. As such, we designed and synthesized a highly effective 
siRNA (siP21) with an empirically calculated IC50 (half maxi-
mal inhibitory concentration) of 4 pmol/l (data not shown). 
Another  siRNA  (siCon)  with  no  known  RNAi  activity  was 
utilized as a control. Combination treatments of siP21 and 
dsP21-322-2′F were performed to identify a minimal effec-
tive concentration of siRNA to compensate for p21 induction. 
As shown in Supplementary Figure S7a, cotreatments with 
0.5 nmol/l siP21 and ~10–15 nmol/l dsP21-322-2′F restored 
p21 expression to near basal levels at 72 hours. However, 
combination treatments with 0.5 nmol/l siCon interfered with 
dsP21-322-2′F activity reducing its EC50 by tenfold (Supple-
mentary Figure S7b,c). Two additional siRNAs (siXBP and 
siSID1) with known function and calculated IC50 values simi-
lar to siP21 also interfered with dsP21-322-2′F activity in a 
manner similar to siCon suggesting co-delivery of multiple 
dsRNAs may interfere with RNAa activity (Supplementary 
Figure S7d,e).
In order to determine if blocking p21 induction by siRNA 
interferes  with  dsP21-322-2′F  function,  cotreatments  were 
performed with 12 nmol/l dsP21-322 to compensate for 0.5 
nmol/l siCon or siP21. As shown in Figure 4a, transfection 
of  dsP21-322-2′F  at  the  proper  ratio  with  siP21  or  siCon 
allowed for minimal changes in p21 expression or induction 
roughly equal to 1 nmol/l dsP21-322-2′F, respectively. Pre-
vention of p21 induction by siP21 also appeared to partially 
interfere with the ability of dsP21-322-2′F to deplete P-Rb 
levels (Figure 4b). Further analysis revealed siP21 altered 
dsP21-322′2F cell cycle distribution resulting in a profile that 
resembled control treatments; restoration in S phase popu-
lation  with  corresponding  depletion  in  G0/G1  cell  number 
 ( Figure 4c,d). Analysis of the gated whole-cell population 
also revealed siP21 partially reduced the number of sub-G1 
cells  in  dsP21-322-2′F  treatments  (Figure  4c,d).  These 
results indicate that the growth inhibitory function of dsP21-
322-2′F is dependent on p21 induction.
Off-target activities of dsP21-322-2′F
Global  deregulation  of  other  cell  cycle-related  genes 
and/or  changes  in  upstream  transcriptional  regulators 
may result in p21 induction via nonspecific mechanisms. 
To  investigate  off-target  activities  of  dsP21-322-2′F,  we 
screened the expression of several cyclin transcripts (i.e., 
CCND1, CCNA1, and CCNE1), CDK inhibitor family mem-
bers (i.e., p16, p15, and p27), and known transcriptional 
regulators of p21 (i.e., SP1, SP3, Myc, E2F1, E2F3, and 
HDAC1)  by  real-time  PCR.35,36  Upstream  factor  p53  was 
not evaluated because PC-3 cells are null for p53 expres-
sion.32 Of the 12 genes, dsP21-322-2′F caused increases 
in  CCNE1,  p15,  and  p27,  as  well  as  reduced  HDAC1 
expression   (Supplementary Figure S8a,b). Deregulation 
in gene expression was not a downstream consequence 
of p21 activation as siP21 blocked p21 induction, but did 
not restore basal levels of CCNE1, p15, p27, or HDAC1 
 ( Supplementary Figure S8c,d).  Selective  knockdown  of 
HDAC1 by siRNA (siHDAC1) did not impact p21 expression; 
however, p15 and p27 levels were elevated by siHDAC1 
(Supplementary  Figure  S8e–g).  These  results  indicate 
dsP21-322-2′F  possesses  off-target  activities;  however, 
p21 activation is independent of HDAC1 depletion.Molecular Therapy–Nucleic Acids
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Lipidoid-mediated delivery of dsP21-322-2′F
Lipidoids  are  a  class  of  liposomal-like  molecules  that 
have been screened for effective in vivo delivery of siRNA 
molecules.5,6  To  determine  if  lipidoids  are  capable  of 
mediating  RNAa,  lipidoid-encapsulated  dsP21-322-2′F 
nanoparticles  (LNP-dsP21-322-2′F)  were  generated  with 
95N12-5(1)  under  parameters  for  maximal  efficacy  and 
tested in vitro for p21 induction. Nonspecific lipidoid-based 
nanoparticles (LNP-dsCon-2′F) were also formulated as a 
control. PC-3 cells were treated with 0–9 μg/ml of LNP-
dsP21-322-2′F  or  LNP-dsCon-2′F  for  72  hours  and  p21 
expression was evaluated by semi-quantitative and real-
time  PCR.  Transfection  of  non-formulated  dsRNA  with 
RNAiMax was used as a positive control for in vitro activity. 
Compared  to    LNP-dsCon-2′F,  LNP-dsP21-322-2′F  incre-
mentally   elevated p21 levels relative to particle concentra-
tion; doses at 9 μg/ml roughly equaled levels in RNAiMax 
treatments (Figure 5a,b). Direct analysis of cellular uptake 
revealed LNP-dsP21-322-2′F at 9 μg/ml effectively deliv-
ered  dsP21-322-2′F  to  levels  comparable  to  RNAiMax 
 ( Supplementary  Figure  S9).  Cumulative  reductions  in 
cell viability also correlated to the incremental increases 
in p21 expression (Figure 5c). By day 5, cell viability con-
tinued to decline in all LNP-dsP21-322-2′F particle treat-
ments (Figure 5d). Although differences in cell viability by 
LNP-dsCon-2′F were all generally nominal, treatments at 
9 μg/ml were found to be statistically significant for minimal 
reductions in cell viability on day 5 (Figure 5c,d).
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Lipidoid-based  particles  can  also  increase  the  nuclease 
resistance of encapsulated siRNA molecules.37 To test the 
effect of lipidoid formulation on dsP21-322-2′F stability, we 
evaluated the nuclease sensitivity of LNP-dsP21-322-2′F in 
active mouse serum. As shown in Figure 5e, LNP-dsP21-322-
2′F was radically more stable than unmodified dsP21-322 or 
unformulated dsP21-322-2′F. Even at 48 hours, low levels of 
LNP-dsP21-322-2′F duplex remained detectable (Figure 5e). 
Quantification of duplex decay estimated the half-life of LNP-
dsP21-322-2′F at ~38 hours   (Supplementary Figure S10).
Lipidoid-formulated  dsP21-322-2′F  inhibits  xenograft 
prostate tumor growth
To  assess  LNP-dsP21-322-2′F  activity  in  vivo,  homozy-
gous athymic nude (nu/nu) male mice were subcutaneously 
  inoculated with PC-3 cells in their lower flanks. After 2 weeks 
when average tumor volume reached ~200 mm3, mice were 
randomly divided into four groups and treated with phosphate-
buffered  saline  (PBS),  LNP-dsCon-2′F,  LNP-dsP21-322, 
or  LNP-dsP21-322-2′F.  Nanoparticles  were  administered 
via intratumoral injection at 5 mg/kg every 3 days for three 
total treatments (Figure 6a). Treatment with PBS served as 
a  procedural  control,  while  lipidoid-formulated  dsP21-322 
(LNP-dsP21-322)  was  utilized  as  a  comparison  treatment 
for LNP-dsP21-322-2′F. Xenografts were grown for a total of 
36 days until animals in control groups met AVMA (  America 
Veterinary  Medical  Association)  guidelines  for  euthanasia 
as  a  result  of  tumor  burden.  All  mice  were  subsequently 
euthanized and tumors surgically removed. Representative 
photographs of mice with subcutaneous masses and their 
Figure 5  Lipidoid-mediated delivery of dsP21-322-2′F. (a) Duplexes were formulated into lipidoid-encapsulated nanoparticles (LNP). 
PC-3 cells were treated with the indicated quantities of LNP-dsCon-2′F or LNP-dsP21-322-2′F for 72 hours. Transfection of non-formulated 
dsCon-2′F or dsP21-322-2′F was performed using RNAiMax and served as controls for in vitro activity. Expression levels of p21 and 
  GAPDH were assessed by semi-quantitative RT-PCR. (b) Relative expression of p21 was determined by real-time PCR (mean ± SD 
from three independent experiments). Values of p21 were normalized to GAPDH. (c) Cell viability was quantified by MTS reagent 3 days 
  following dsRNA treatments. Data is plotted as the mean ± SD of three independent experiments relative to untreated cells (0 μg/ml). 
(d) Cell viability at day 5 following dsRNA treatments. Statistical significance (**P < 0.05) of changes in cell viability by LNP-dsCon-2′F 
were determined by two-tailed t-test against untreated cells (0 μg/ml). (e) Equal quantities of dsRNA were diluted in active mouse serum 
and incubated at 37 °C for the indicated lengths time. Duplex stability was visualized on an agarose gel. dsRNA, double-stranded RNA; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium; RT-PCR, reverse transcription-PCR.
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corresponding  tumors  are  indicated  in  Figure  6b.  Tumor 
volume was also recorded periodically following initial treat-
ments. As shown in Figure 6c, both LNP-dsP21-322 and 
LNP-dsP21-322-2′F treatment groups recorded reductions in 
xenograft volume compared to control groups. It is important 
to note that tumor volume was recorded using the modified 
ellipsoidal formula in which dimensions of only length and 
width were utilized to calculate tumor capacity. As tumor size 
visually depleted, white disc-like masses remained under the 
skin where the tumors once resided (Figure 6b). Because it 
was unclear if this white subcutaneous tissue was still tumor, 
it was included in the measurements to calculate tumor vol-
ume. It was not until the tumors were excised that the white 
mass was revealed to be fatty and/or scarred tissue. As such, 
estimation of tumor volume was generous in regards to actual 
tumor size.
Further analysis of gross tumor weight revealed significant 
reductions in LNP-dsP21-322 and LNP-dsP21-322-2′F treat-
ment groups compared to controls (Figure 6d). Tumor-to-body 
weight ratios were also significantly lower in LNP-dsP21-322 
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Figure 6  Reduction of xenograft prostate tumor growth by LNP-dsP21-322-2′F.  (a) Experimental timeline and dosing schedule 
for mice treated with LNP-formulated dsRNA via intratumoral injection. The timeline corresponds to weeks following tumor inoculation.   
(b) Representative photographs of mice with subcutaneous masses (arrows) and corresponding tumors following surgical resection. Each 
tick mark on the ruler corresponds to 1 mm. (c) Subcutaneous tumor dimensions were recorded using calipers at the indicated time points 
  following initial dsRNA treatment. Tumor volume was estimated using the modified ellipsoidal formula. Data is plotted as the mean volume ± 
SD (n = 10 for each group). (d) Tumor weight was recorded at time of harvest and plotted according to treatment group. Mean tumor weight 
(g) and statistical significance is indicated. (e) Tumor-to-body weight ratio for each animal was plotted according to treatment group. A tumor- 
to-body weight ratio ≤0.01 signifies low tumor burden as delineated by the dotted line. Statistical analyses were calculated by two-tailed t-test 
between indicated groups. dsRNA, double-stranded RNA; LNP, lipidoid-encapsulated nanoparticles; PBS, phosphate-buffered saline.www.moleculartherapy.org/mtna
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and LNP-dsP21-322-2′F treatment groups signifying a reduc-
tion in tumor burden (Figure 6e). It should be noted that the 
LNP-dsP21-322-2′F treatment group possessed less variation 
in tumor weight and burden compared to its unmodified form.
Immunohistochemistry (IHC) revealed that p21 was virtu-
ally undetectable in LNP-dsP21-322-2′F-treated xenografts 
~3 weeks following initial doses (data not shown). Because 
of the reduction in tumor size, cells positive for p21 induction 
may have dissipated before analysis. To assess p21 activa-
tion in vivo, tumors were removed from mice 3 days following 
the final dose of lipidoid nanoparticles and processed for IHC 
(Figure 7a). As shown in Figure 7b, staining for p21 in con-
trol treatments was generally infrequent; any cells positive for 
p21 were randomly dispersed throughout the control tissues. 
In contrast, isolated areas of intense nuclear staining were 
detectable within the LNP-dsP21-322-2′F-treated xenografts. 
Increased levels of p21 were also detectable by immunoblot 
analysis in protein extracts prepared from total homogenized 
tissue (Figure 7c). These results suggest that p21 was acti-
vated in vivo by intratumoral delivery of LNP-dsP21-322-2′F.
Discussion
In the present study, we implement RNAa to explore the ther-
apeutic potential of p21 induction in human prostate cancer 
xenografts by utilizing a lipidoid-based delivery vehicle. Lipi-
doid formulations are one of the leading materials for stabiliz-
ing and improving the bioavailability of siRNAs in vivo.5,6,37 
Our results provide proof-of-principle that lipidoids are also 
effective in delivering RNA duplex to facilitate p21 induction 
and inhibit prostate cancer cell growth.
In PC-3 cells, dsP21-322-2′F resulted in robust induction 
of p21 with corresponding reductions in Rb phosphorylation. 
Although Rb is an important mediator of p21, it is not the only 
means by which p21 can suppress cell growth. For example, 
p21 can inhibit proliferating cell nuclear antigen function and/
or interfere with the activity of several oncogenic transcrip-
tion factors (i.e., E2F1, Myc, etc.).16 As such, induction of 
p21 by dsP21-322-2′F may have therapeutic benefit in can-
cer regardless of Rb status. In support, dsP21-322-2′F was 
capable of activating p21 and reducing viability in cell lines 
containing inactive (DU-145) or wild-type (PC-3 and LNCaP) 
Rb protein.
Although the growth inhibitory functions of dsP21-322-2′F 
depends on p21 induction, siP21 cotreatments did not com-
pletely restore PC-3 cells to a basal phenotype. For instance, 
siP21 appeared to only partially restore phosphorylated Rb 
levels to baseline and a significant fraction of sub-G1 cells 
remained in siP21 and dsP21-322-2′F cotreatments. Although 
these results may arise from the method utilized to compen-
sate for p21 induction, it cannot rule out the possibility that 
some of the growth inhibitory functions of dsP21-322-2′F may 
result from nonspecific or off-target effects. Expression analy-
sis of 12 additional cell cycle regulators and transcription fac-
tors revealed dsP21-322-2′F also deregulated CCNE1, p15, 
p27, and HDAC1. Presumably, activation of CCNE1 did not 
contribute  to  the  growth  arrest  effects  of  dsP21-322-2′F; 
CCNE1 is known to accumulate in G1 phase to promote cell 
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Figure 7  p21 induction by LNP-dsP21-322-2′F in xenograft prostate tumors. (a) Experimental timeline for immunodetection of p21 
in xenograft prostate tumors. The timeline corresponds to weeks following tumor inoculation. (b) Representative microphotographs of p21 
staining in tissue slides prepared from PBS, LNP-dsCon-2′F, and LNP-dsP21-322-2′F-treated xenografts. Arrow heads indicate area of 
intense staining in the LNP-dsP21-322-2′F-treated sample. Enlarged images show nuclear location of p21. (c) Whole tumor tissue was 
  homogenized and p21 induction was confirmed by immunoblot analysis. Detection of GAPDH served as a loading control. Nonspecific 
(NS) protein bands also correspond with loading efficiency. Samples of LNP-dsP21-322-2′F treatments are from two separate tumors. 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LNP, lipidoid-encapsulated nanoparticles; PBS, phosphate-buffered saline.Molecular Therapy–Nucleic Acids
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cycle progression.38 As such, its upregulation may indirectly 
result from dsP21-322-2′F-induced G1 arrest and/or accumu-
lation of CDK inhibitors (i.e., p21, p27, and p15). The down-
regulation of HDAC1 may have occurred through a canonical 
mechanism of RNAi; in silico analysis of the HDAC1 tran-
script reveals several possible sites semi-complementary to 
dsP21-322-2′F (data not shown). Previous studies have linked 
HDAC1 suppression to activation of CDK inhibitors (e.g., p21, 
p27, etc.).36,39,40 Although p21 induction was independent of 
HDAC1, its knockdown elevated p15 and p27 levels in PC-3 
cells. This  may  suggest  that  activation  of  p15  and  p27  by 
dsP21-322-2′F derives from HDAC1 depletion contributing, in 
part, to Rb hypophosphorylation and growth inhibition.
Characterization  of  off-target  transcripts  also  indirectly 
evaluates target specificity. For instance, the expression of 
several key upstream regulators (i.e., SP1, SP3, Myc, E2F1, 
and  E2F3)  were  unaffected  by  dsP21-322-2′F  removing 
them as candidates for modes of nonspecific gene induction. 
In addition, HDAC1 was determined to be reduced by dsP21-
322-2′F; however, its selective knockdown had no impact on 
p21 expression. While dsP21-322-2′F possesses off-target 
activity,  none  of  the  evaluated  genes  accounted  for  p21 
induction. Three additional dsRNAs (i.e., dsP21-254, dsP21-
280, and dsP21-402) were also determined to induce p21 
expression by varying magnitudes. If taken into consideration 
that each activator possesses a different “seed” sequence 
and targets non-overlapping regions, the likelihood for each 
duplex functioning via suppression of nonspecific upstream 
regulators is potentially low.
Conventional RNAi requires high degrees of complemen-
tarity  with  the  target  transcript  for  effective  cleavage  and 
gene  silencing.41,42  However,  previous  studies  have  con-
cluded that cleavage of target molecule(s) may not be neces-
sary for mechanisms of RNAa.15,43 In support, analysis of the 
mutant derivatives revealed that mismatches to the center of 
dsP21-322-2′F did not interfere with p21 induction, although 
sequence corresponding to the “seed” and 3′-flanking regions 
were essential for optimal function. Although cleavage activ-
ity may not be required for RNAa, extended complementarity 
in the 3′-flanking region is important for effective p21 induc-
tion by dsP21-322-2′F.
Concurrent use of both RNAi and RNAa may have coopera-
tive effects in controlling cell phenotype. However, cotreatment 
with siRNA interfered with dsP21-322-2′F activity reducing its 
EC50 by approximately tenfold. Competition between siRNAs 
has been reported in which delivery of multiple siRNAs hin-
ders with the efficacy of the individual reagents.44,45 In this 
regards, co-delivery of multiple duplexes may similarly inter-
fere with RNAa activity.
Being that p21 is seldom inactivated in human cancers, 
its  upregulation  may  also  benefit  in  treatment  of  other 
tumors.24–26  Lipidoid  formulations  are  preferentially  being 
developed to target the liver based on natural accumulation 
in hepatic tissue.5 In this regards, LNP-dsP21-322-2′F may 
have practical therapeutic application in liver cancer. In addi-
tion, it is quite possible that the other activators (dsP21-254, 
dsP21-280, and dsP21-402) may have therapeutic function 
in context to different cells, tissue, and/or cancer. However, 
caution may need to apply as p21 has been shown to cor-
relate with nonconventional activities such as oncogenicity 
under certain conditions. For example, overexpression of p21 
in the cytoplasmic compartment has been associated with 
poor prognosis in select cancers.46–48 Although this function 
is less understood, its oncogenic activities may be dependent 
on nontraditional cytoplasmic targets of the protein. As such, 
features like localization and/or basal overexpression of p21 
may need to be considered before therapeutic development 
in other cancers.
Lipidoid  formulation  of  dsP21-322-2′F  (LNP-dsP21-322-
2′F) exhibited more consistent reduction in tumor size than its 
unmodified variant (LNP-dsP21-322). Perhaps, this may be 
attributed to the enhanced medicinal properties associated 
with dsP21-322-2′F. With a more refined treatment regime, 
the therapeutic efficacy of LNP-dsP21-322-2′F may be fur-
ther enhanced in the xenograft model. For instance, long-term 
therapeutic application would benefit from recurring doses of 
LNP-dsP21-322-2′F. Additional chemical modifications would 
also be mandatory to further improve its medicinal properties. 
For instance, 2′-fluoro modification at additional positions may 
remove residual immunostimulatory effects. Although dsP21-
322-2′F  possesses  off-target  function,  HDAC1  is  a  thera-
peutic target frequently overexpressed in numerous cancers 
types (e.g., prostate).40,49 Its knockdown may be a beneficial 
off-target  consequence  for  inhibiting  cancer  cell  growth.40 
Nonetheless, LNP-dsP21-322-2′F is a putative RNAa-based 
therapeutic with antitumor activity. Although lipidoids are pref-
erentially utilized to target the liver, they may also function to 
deliver RNA duplexes locally to organs such as the prostate—
accessible through a relatively small layer of soft tissue. LNP-
dsP21-322-2′F may be administered with a small needle in a 
manner similar to the xenograft treatments and/or accompany 
biopsy procedures. However, improvement and/or discovery 
of novel in vivo delivery systems would ultimately benefit its 
therapeutic efficacy in prostate cancer. For instance, conjuga-
tion to an anti-PSMA aptamer may allow for systemic delivery 
of dsP21-322-2′F to PSMA-positive prostate cancer cells in 
a manner similar to siRNA-aptamer chimeras.50 Our results 
demonstrate that lipidoid formulation can mediate RNAa both 
in vitro and in vivo by delivering dsP21-322-2′F to activate 
p21 expression and inhibit growth of prostate cancer cells. 
These findings suggest that RNAa in conjunction with lipi-
doids or other delivery systems may represent a novel thera-
peutic approach for enhancing endogenous gene expression 
and combating disease at the genetic level.
Materials and methods
Cell culture and dsRNA transfection. Human prostate can-
cer cell lines (PC-3, LNCaP, and DU-145) were maintained 
in RPMI 1640 medium supplemented with 10% fetal bovine 
serum,  l-glutamine  (2  mmol/l),  penicillin  (100  U/ml),  and 
streptomycin  (100  μg/ml)  in  a  humidified  atmosphere  of 
5% CO2 at 37 °C. The day before dsRNA transfection, cells 
were plated in growth medium without antibiotics at a density 
of ~50–60%. Transfection of dsRNA was carried out using 
Lipofectamine RNAiMax (Invitrogen, Carlsbad, CA) accord-
ing  to  the  manufacturer’s  instructions.  All  duplexes  were 
synthesized by Invitrogen and/or Alnylam Pharmaceuticals 
(Cambridge, MA). Production of 2′-fluoro-modified dsRNAs www.moleculartherapy.org/mtna
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were performed exclusively by Alnylam Pharmaceuticals. All 
dsRNA sequences are listed in Supplementary Table S1.
Cell stimulation and cytokine production. Whole blood from 
3  anonymous  donors  was  obtained  from  Research  Blood 
Components  (Brighton,  MA)  and  pre-screened  for  infec-
tious  agents.  Human  peripheral  blood  mononuclear  cells 
were isolated by Ficoll gradient centrifugation and plated in 
96-well microplates at ~100,000 cells per well. Transfection of 
dsRNA was carried out using DOTAP (Roche, Indianapolis, 
IN) according to the manufacturer’s protocol. Supernatants 
were harvested ~24 hours after transfection and immediately 
assayed for IFN-α and TNF-α production by ELISA (Bender 
Medsystems, Vienna, Austria). Each treatment was analyzed 
in triplicate for all three donors.
Establishing xenograft prostate tumors. All xenograft stud-
ies were performed according to protocol approved by the 
Institutional Animal Care and Use Committee (IACUC). PC-3 
cells were cultured at a density of ~70–80% in 150 mm plates. 
Cells were trypsinized and centrifuged at 1,500 rpm for 5 
minutes in complete medium. Cell pellets were subsequently 
washed and resuspended in PBS containing Matrigel (BD 
Biosciences, San Jose, CA) for in vivo inoculation. Homozy-
gous athymic nude (nu/nu) male mice at 4–6 weeks of age 
were purchased from Simonsen Laboratories (Gilroy, CA). 
After 5 days of acclimation, animals were subcutaneously 
inoculated in their lower flanks with PC-3 cells (3 × 106) sus-
pended in 0.2 ml of PBS containing Matrigel. Tumor volume 
was monitored by digital calibers and calculated using the 
modified ellipsoidal formula: tumor volume (mm3) = (width)2 × 
length/2. Mice were examined weekly for body weight and 
overall health. The study ceased when the first animals met 
AVMA guidelines for euthanasia as a result of tumor burden.
Intratumoral delivery of lipidoid-formulated dsRNA. Two weeks 
after inoculation, tumor-bearing mice were randomly divided 
into four treatment groups (PBS, LNP-dsCon-2′F, LNP-dsP21-
322, and LNP-dsP21-322-2′F) each containing 10–12 animals. 
Lipidoid-formulated dsRNA was administered via intratumoral 
injection at 5 mg/kg every 3 days for three total doses. PBS 
treatments  were  performed  at  volumes  equivalent  to  LNP-
dsP21-322-2′F  doses.  Sequences  to  all  lipidoid-formulated 
dsRNAs are available in Supplementary Table S1.
Immunodetection  in  xenograft  tissue.  Mice  were  eutha-
nized and tumors surgically resected according to protocols 
approved by the IACUC. Animals from treatment groups with 
more than 10 mice (PBS, LNP-dsCon-2′F, and LNP-dsP21-
322-2′F) were killed early (3 days after final LNP dose) for 
prompt immunoanalysis. Tumors from all remaining animals 
were harvested at the conclusion of the study. Each tumor 
was divided in half and placed in either radioimmunoprecipi-
tation assay (RIPA) buffer containing protease inhibitors or 
10% neutral buffered formalin for immunoblot analysis or IHC, 
respectively. The formalin-fixed tissue was eventually embed-
ded in paraffin blocks, cut into 5 μm sections, and mounted 
onto glass slides. IHC was initiated by paraffin removal and 
rehydrating tissue sections in water. Slides were subsequently 
boiled in 10 mmol/l citrate, pH 6.0 for 15 minutes to improve 
antigen recovery and treated with 3% hydrogen peroxide for 
5 minutes. Afterward, sections were blocked in Tris-buffered 
saline (TBS) containing 0.1% Tween 20 and 5% goat serum 
for 1 hour. Immunodetection proceeded by incubating slides 
overnight at 4 °C with primary antibody specific to p21 (Cell 
Signaling Technology, Danvers, MA) diluted 1:500 in blocking 
solution.  Slides  were  subsequently  incubated  with  biotiny-
lated secondary antibody and stained using the Elite ABC kit 
(Vector Laboratories, Burlington, CA) in conjunction with per-
oxidase substrate. An antibody specific to normal rabbit IgG 
(Cell Signaling Technology) was also utilized as a nonspecific 
control and generated no detectable staining. All slides were 
counterstained with hematoxylin.
Other experimental procedures are available in Supple-
mentary Materials and Methods
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